📊 PAVM Key Takeaways
Is PAVmed Inc. (PAVM) a Good Investment?
PAVmed has experienced a catastrophic operational collapse with revenue declining 97.6% YoY to just $71K, while the company burns $5.2M annually in operating cash. With only $1.5M cash remaining and a critical liquidity crisis (current ratio 0.17x), the company has approximately 3-4 months of runway at current burn rates.
Why Buy PAVmed Inc. Stock? PAVM Key Strengths
- Moderate debt-to-equity ratio of 0.23x indicates low financial leverage relative to equity base
- Maintains $34M in stockholders equity on balance sheet providing potential asset value
- Long-term debt of $7.8M is manageable relative to asset base
PAVM Stock Risks: PAVmed Inc. Investment Risks
- Revenue collapsed 97.6% YoY to $71K, indicating fundamental business model failure
- Severe liquidity crisis with current ratio of 0.17x and insufficient cash to cover current liabilities
- Operating cash flow of -$5.2M annually with only $1.5M cash creates imminent solvency risk
- Negative gross margin of -253.5% indicates operations are unprofitable on sales
- Operating loss of $21.8M in latest period with negative operating margins exceeding -30,000%
- Extremely limited cash runway of approximately 3-4 months at current burn rate
Key Metrics to Watch
- Monthly cash burn rate and remaining liquidity runway
- Sequential quarterly revenue trend and stabilization indicators
- Working capital position and current ratio trajectory
PAVmed Inc. (PAVM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PAVM Profit Margin, ROE & Profitability Analysis
PAVM vs Healthcare Sector: How PAVmed Inc. Compares
How PAVmed Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is PAVmed Inc. Stock Overvalued? PAVM Valuation Analysis 2026
Based on fundamental analysis, PAVmed Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
PAVmed Inc. Balance Sheet: PAVM Debt, Cash & Liquidity
PAVM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: PAVmed Inc.'s revenue has grown significantly by 499% over the 5-year period, indicating strong business expansion. The most recent EPS of $14.90 reflects profitable operations.
PAVM Revenue Growth, EPS Growth & YoY Performance
PAVM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $5.0K | $1.7M | $-0.11 |
| Q2 2025 | $6.0K | $7.0M | $0.13 |
| Q1 2025 | $8.0K | -$15.2M | $0.34 |
| Q3 2024 | $791.0K | -$17.7M | $0.79 |
| Q2 2024 | $166.0K | -$10.8M | $-1.19 |
| Q1 2024 | $446.0K | -$15.2M | $-2.62 |
| Q3 2023 | $76.0K | -$17.7M | $-0.16 |
| Q2 2023 | $166.0K | -$14.5M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
PAVmed Inc. Dividends, Buybacks & Capital Allocation
PAVM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for PAVmed Inc. (CIK: 0001624326)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PAVM
What is the AI rating for PAVM?
PAVmed Inc. (PAVM) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PAVM's key strengths?
Claude: Moderate debt-to-equity ratio of 0.23x indicates low financial leverage relative to equity base. Maintains $34M in stockholders equity on balance sheet providing potential asset value.
What are the risks of investing in PAVM?
Claude: Revenue collapsed 97.6% YoY to $71K, indicating fundamental business model failure. Severe liquidity crisis with current ratio of 0.17x and insufficient cash to cover current liabilities.
What is PAVM's revenue and growth?
PAVmed Inc. reported revenue of $71.0K.
Does PAVM pay dividends?
PAVmed Inc. does not currently pay dividends.
Where can I find PAVM SEC filings?
Official SEC filings for PAVmed Inc. (CIK: 0001624326) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PAVM's EPS?
PAVmed Inc. has a diluted EPS of $-5.63.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PAVM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, PAVmed Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PAVM stock overvalued or undervalued?
Valuation metrics for PAVM: ROE of 1.2% (sector avg: 15%), net margin of 564.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PAVM stock in 2026?
Our dual AI analysis gives PAVmed Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is PAVM's free cash flow?
PAVmed Inc.'s operating cash flow is $-5.2M, with capital expenditures of $31.0K. FCF margin is -7,376.1%.
How does PAVM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 564.8% (avg: 12%), ROE 1.2% (avg: 15%), current ratio 0.17 (avg: 2).